🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

$RIGL #news - Positive topline data shows #fostamatinib met the primary endpoint of safety in Phase 2 #clinicaltrial in hospitalized patients with #COVID19 - rigel.com/investors/news…

Fostamatinib: Ruxolitinib: SoC in COVID-19 patients from admission. Imperial College London Imperial NHS 💙 study now multi-site NIHR Imperial BRC Imperial Department of Immunology & Inflammation Plus Rigel Pharmaceuticals +ve top line data on primary safety end point with Fostamatinib in COVID-19 rigel.com/investors/news…

www2.mrc-lmb.cam.ac.uk/evolutionary-j…

Reason #2: in severe COVID-19 patients, the Fc tail of anti-Spike IgG is aberrantly glycosylated (different sugar groups). For details see our previous study in Science Magazine: science.sciencemag.org/content/371/65… 7/14

So is there any way we prevent this? Yes, there may be! We identified that the drug fostamatinib (Syk inhibitor) can specifically counteract all of these effects. This drug is now in Phase 3 clinical trials, after successful Phase 2: rigel.com/investors/news… 8/14

Paper in Journal of Thrombosis and Haemostasis comparing 43 samples tested for VITT using 10 different assays. Clearly shows that you should be using a HIT ELISA assay. tinyurl.com/h688469s #VITT

Truly wonderful video of clinical research Imperial NHS 💙 Imperial Medicine #COVID19 research including our evidence based Treatment group. Proud to be a small part of this: Hannah Pluthero 💙 Graham Cooke Mark Gilchrist Prof Liz B 🇬🇧🇮🇱🇺🇦🇵🇸 Nichola Cooper Anthony Gordon MATIS remap-cap

Full video here: youtube.com/watch?v=u7NNix… (No I don’t appear 😉)

We are delighted to announce that the Royal College of Physicians have reviewed and endorsed the clinical content of our ITP shared decision-making toolkit. The toolkit can be downloaded at bit.ly/3nBA2pb or email [email protected] for a hard copy.”

You can download a copy for FREE of our highly regarded - Making the right choices in ITP management and care itpsupport.org.uk/index.php/en/h…

⁦Nichola Cooper⁩ Back in venue, register now for ITP Update Day - Friday 6th May at hartleytaylor.co.uk/itp3-home/

Great collaboration with Emma Davenport, Nichola Cooper and Graham P Taylor, and shoutout to Katie L Burnham and Allison Maher who did most of the work!

Efficacy, Safety, Viral Clearance and Antibody Response in those receiving Tocilizumab for COVID-19 pneumonia Important and unique data not collected by the other large trials sciencedirect.com/science/articl… Nichola Cooper Sanjay Bhagani Siniša Savić and co Roche

Thank you Imperial Health Charity for the tickets to V&A corporate evening, we loved it! A great team night out 🎭 #faberge #beatrixpotter #fashioningmasculinities

Thank you

Good news for some #immunosuppressed #patients - #VROOM study showed #rheumatoid #arthritis patients stopped #methotrexate for 2 weeks they had #CovidVaccine antibody response. Kudos to Taryn Youngstein for leading the Imperial NHS 💙 part of the trial 1/ bbc.co.uk/news/health-61…

#Immune thrombocytopenia is considered an #antibody-mediated disease. However, a number of features suggest alternative methods of #platelet 🩸 destruction, like CD8+ T cell clones studied by Dr. Nichola Cooper's team at Imperial Department of Immunology & Inflammation! @BloodJournal | bit.ly/3K5UhGF

ITP is an autoimmune dse in w/c the immune system mistakes the platelets as being foreign & destroys them.Today we have raised awareness Imperial NHS 💙 &received a lot of engagement from the public Imperial People 💙 Non-Malignant Haematology Research @ Imperial NHS Nichola Cooper DeeNa Karen Bradley 💙